Neuroplast Completes Phase II Clinical Trial Inclusion for Traumatic Spinal Cord Injury
Neuroplast, a Dutch clinical-stage biotech company, has successfully concluded the patient inclusion for its Phase II clinical trial, focusing on Traumatic Spinal Cord Injury (TSCI). Here are the key details: Thought-Provoking Questions/Insights: Original Press Release